To D or Not to D? That is the Question: Not All Anti-D Reagents Are the Same

Myth: All anti-D reagents detect the D antigen equally well — one reagent is as good as another.

In immunohematology, one persistent misunderstanding is the assumption that all anti-D reagents detect the RhD polypeptide identically. In reality, the diversity of monoclonal antibody clones and isotypes that can be used to manufacture of anti-D reagents makes them highly variable for the detection of the D antigen, and this variability can have significant clinical consequences in transfusion medicine and obstetrics.

The Complex Nature of the RhD Antigen

The variable reactivity is due to the complex nature of the RhD antigen. RhD is composed of multiple epitopes encoded by the RHD gene, and its expression can vary due to genetic polymorphisms. As a result, individuals with so-called partial D or weak D variants may express only a subset of the full D epitopes. This diversity challenges the development of monoclonal anti-D reagents because different clones recognize different D epitopes.

Distinction of the Partial DVI Variant

Some anti-D reagents contain a mixture of IgM monoclonal antibodies, reactive in an immediate-spin (IS) test. The reagents are convenient to use and identify a broad range of RhD variants. Others are blends of IgM and IgG, suitable for both IS and indirect antiglobulin test (IAT) phases – these are recommended for patient testing. Only the IS phase is performed on transfusion recipients and in pregnancy without extending to IAT phase in order to avoid misclassifying some weak or partial D variants as RhD positive. Certain gel card systems include anti-D reagents specifically formulated as DVI- or DVI+, enabling distinction of the partial DVI variant in patient versus donor testing.  Still others incorporate human plasma sourced polyclonal anti-D at the IAT phase, which offers broad epitope coverage.

Molecular Testing to Resolve RhD Discrepencies

The problem arises when a reagent lacks the ability to detect certain D variant phenotypes which leads to discrepant results between reagents and methods. For instance, transfusion recipients and pregnant women with a partial DVI variant may be typed as RhD-positive using certain monoclonal reagents. If these individuals receive RhD-positive blood or fail to get RhIG antenatal prophylaxis, they risk developing allo-anti-D. Transfusion guidelines now recommend molecular testing to resolve RhD discrepancies and to identify weak D types 1, 2, 3 that can be deemed RhD-positive for transfusion and in pregnancy since they do not make anti-D.

Misunderstanding Reagent Design Highlights Why Selection Matters.

Unfortunately, reagent differences are often overlooked in choosing a reagent and causes confusion. The misunderstanding of reagent design highlights why selection matters. The choice of anti-D reagent should be based not only on regulatory standards, but also on the intended population and clinical context. For example, maternal RhD typing should always use a reagent that is initially nonreactive with the partial DVI or a method capable of discriminating this partial D variant since misclassification (calling a partial DVI mother “Rh-positive” when she can actually form anti-D) could result in withholding Rh immune globulin (RhIG) and risking alloimmunization. Regulatory frameworks (e.g. FDA or European CE marking) set high standards for reagent specificity and sensitivity. Beyond these requirements, further evaluation in diverse patient populations-such as those of African, Asian, or Latin American ancestry where RHD variants occur more frequently-adds clinical value. Since it is not feasible to test reagents against every possible variant phenotype before approval, real-world studies remain an important complement. 

In summary, anti-D reagents are not interchangeable. They differ in sensitivity, epitope recognition, and compatibility with different testing platforms. Understanding these differences is crucial for safe transfusion, accurate typing, and effective RhIG administration. Just as no two patients are alike, no two anti-D reagents are exactly alike either. Want to know more? Click here